Navigation Links
Pharmatech Oncology Launches New Data Management Business Unit
Date:4/24/2009

DENVER, April 24 /PRNewswire/ -- Pharmatech Oncology, Inc., a Research Management Organization (RMO) headquartered in Denver, Colorado, announces the launch of their Data Management business unit to the bioscience and pharmaceutical industries. The Pharmatech Oncology Data Management business unit is branded as C(3)DM (Customized, Consistent, and Clinical Data Management). The Data Management business unit maintains and processes data for a broad range of clinical trials in various therapeutic areas, not only in the fields of oncology and hematology.

In managing clinical data projects, the C(3)DM business unit has built a solid data system platform focused around the EDC (electronic data capture) solution TrialMaster(TM) from OmniComm Systems, Inc.(TM) The platform is designed to be customized to incorporate all of the clinical data aspects involved in each individual clinical trial. "The Data Management team has worked extremely hard over the last few months to develop a fully-integrated solution for data capture and patient accrual for a lymphoma trial. Our unique platform gives clients access to a wide-range of capabilities by having their data managed through a trusted and reliable source, while also having our clinical sites trained by the creators of the system," states Jason Lones, Clinical Data Manager.

The data management business unit focuses on customized data capture solutions for any clinical development marketplace. Data integrity throughout the data management process is assured by following FDA regulations, adhering to industry standard GCPs, and maintaining 21CFR Part 11 compliance.

About Pharmatech Oncology:

Pharmatech Oncology, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech Oncology provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. The Data Management business entity manages data for all types of clinical research, along with in-house trials focused in oncology and hematology. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech Oncology, please visit www.pharmatechoncology.com.

About OmniComm:

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's client intuitive pricing model allows companies that range from small, to mid-size to large scale institutions to safely and efficiently capitalize on their clinical research investments. OmniComm Systems, Inc. has corporate headquarters in Ft. Lauderdale, Florida with offices in Bonn, Chicago, Germany, Tula, Russia, California, New York, North Carolina, Tennessee, Massachusetts and Georgia.

Key Words: Cancer, Clinical Trials, Contract Research, Data Management, Network, Oncology, Patients, Research, Site Management


'/>"/>
SOURCE Pharmatech Oncology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. WuXi PharmaTech Schedules Fourth Quarter 2008 Earnings Release on Thursday, March 26, 2009
2. WuXi PharmaTech Announces CFO Benson Tsang to Leave Company; COO Edward Hu Named Acting CFO
3. WuXi PharmaTech Honored on the Deloitte Technology Fast 500 Asia Pacific 2008 List for the Fifth Consecutive Year
4. WuXi PharmaTech Appoints Stewart Hen and Ning Zhao to Its Board of Directors; Tao Lin Leaves Board
5. WuXi PharmaTech to Present at 20th Annual Piper Jaffray Healthcare Conference
6. WuXi PharmaTech Expands Collaboration for Fully Integrated Services
7. WuXi PharmaTech Announces Second Quarter 2008 Results
8. WuXi PharmaTech (NYSE: WX) Appoints Mr. Steven M. Hutchins as VP of Business Development
9. Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry
10. WuXi PharmaTech 2007 Annual Report Available Online
11. The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... 12, 2016 , ... Miami Dental Specialists is excited to bring patients the ... Beginning in January, Miami Dental Specialists will offer the non-metal implants as a safe, ... to be chosen by the dental implant manufacturer, Straumann, to bring this cutting-edge technology ...
(Date:2/12/2016)... ... February 12, 2016 , ... J Thomas & ... continuing it’s commitment to act as Agents of Change in the community, announces ... area homeless families to fulfill immediate needs and help them move into permanent ...
(Date:2/12/2016)... ... February 12, 2016 , ... Nearly every health website ... health. These articles generally list between five and 15 foods that should be ... every one of these lists and believes that nutritious eye healthy foods are ...
(Date:2/12/2016)... ... February 12, 2016 , ... Homeowners now have a next ... North America’s leading brand of building products, has improved upon its industry-best array ... mobile version of the ColorView® Exterior Style and Color Selector. Created expressly for ...
(Date:2/12/2016)... Colo. (PRWEB) , ... February 12, 2016 , ... A ... the past 35 years. A president has access to health and wellness resources most ... the free world, no single individual has a schedule as frenetic as the U.S. ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016 The primary goal ... future adoption patterns on the usage of liquid biopsy. ... following: - Timeframe of liquid biopsy adoption ... cfDNA and Evs—by organization type - Sample inflow to ... blood, saliva, stool, serum, and so on. - Correlation ...
(Date:2/11/2016)... PRO-DEX, INC. (NasdaqCM: PDEX) today announced financial results for its ... also filed its Quarterly Report on Form 10-Q for the ... Exchange Commission today. --> --> ... --> Net sales for the three months ... $5.4 million from $2.8 million for the three months ended ...
(Date:2/11/2016)... 2016  Kindred Biosciences, Inc. (NASDAQ: KIN ), ... lives of pets, today announced the submission to FDA ... Drug Application (NADA) for Zimeta™ (dipyrone injection, KIND-012).  Positive ... Zimeta for the control of pyrexia (fever) in horses ... --> --> The Chemistry, Manufacturing, and ...
Breaking Medicine Technology: